# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Buy and maintains $9...
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative med...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Buy and maintains $9...
Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate o...
Canaccord Genuity analyst Whitney Ijem maintains Regulus Therapeutics (NASDAQ:RGLS) with a Buy and lowers the price target f...
Leerink Partners analyst Joseph Schwartz initiates coverage on Regulus Therapeutics (NASDAQ:RGLS) with a Outperform rating a...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:RGLS) with a Buy and maintains $9...
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarte...